Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy AGL?
Source: Benzinga
- Reverse Split Announcement: Ryvyl Inc's announcement of a 1-for-35 reverse stock split to regain Nasdaq's $1 minimum bid compliance led to a pre-market plunge of 14.4% in share price to $0.13, indicating a significant loss of investor confidence and potential liquidity issues.
- Market Reaction: Following the reverse split news, Ryvyl's shares fell sharply, reflecting market concerns about the company's future prospects, which could hinder its ability to raise capital and maintain competitive positioning.
- Other Stock Movements: Shares of Mink Therapeutics and SMX dropped 13.4% and 8.2% respectively, illustrating a broader market sentiment decline that may negatively impact investor confidence across related sectors.
- Industry Impact: Despite NeoGenomics' 7.1% decline in share price, the appointment of industry veteran John P. Kenny to its Board may provide a strategic turning point for the company, potentially enhancing its competitive edge in the diagnostics and lab services market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 0.98 USD with a low forecast of 0.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
1 Buy
7 Hold
2 Sell
Hold
Current: 0.631
Low
0.50
Averages
0.98
High
1.50
Current: 0.631
Low
0.50
Averages
0.98
High
1.50
About AGL
agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Agilon Health, Inc., involving investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false or misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon executives knowingly issued unattainable financial guidance amidst significant industry challenges and overstated the immediate financial impact of their 'strategic actions,' leading to materially false perceptions of the company's business and prospects among investors.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Potential Compensation Opportunity: Participants may receive compensation through a contingency fee arrangement without upfront costs, indicating that the lawsuit offers legal support to investors without additional financial burden, potentially attracting more affected investors.
- Lawsuit Background: The lawsuit alleges that Agilon Health made misleading financial guidance during the class period, resulting in investor losses once the true details were revealed, highlighting management failures in addressing industry challenges.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Agilon Health and certain officers, alleging violations of federal securities laws on behalf of investors who purchased Agilon securities between February 26, 2025, and August 4, 2025, seeking damages for affected parties.
- False Statement Allegations: The complaint claims that throughout the class period, defendants made false and/or misleading statements and failed to disclose significant industry headwinds that would prevent them from achieving their 2026 financial guidance, misleading investors about the company's prospects.
- Exaggerated Financial Impact: Defendants are accused of materially overstating the immediate positive financial impact of strategic actions taken by Agilon, resulting in materially false and/or misleading statements regarding the company's operations and future outlook at all times.
- Investor Action Recommendation: Affected investors have until March 2, 2026, to request to be appointed as lead plaintiff, allowing them to participate in any potential recovery, with the lawsuit not requiring them to serve as lead plaintiff to share in any recovery.
See More
- Investor Rights Protection: Faruq & Faruqi LLP is investigating potential claims against agilon health, particularly for investors who purchased securities between February 26, 2025, and August 4, 2025, aiming to safeguard investor legal rights.
- Litigation Deadline Reminder: The firm reminds investors that March 2, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating timely action from investors to protect their interests.
- Legal Consultation Channels: Investors who have suffered losses can directly contact Faruqi & Faruqi partner Josh Wilson, with multiple contact options provided to facilitate investor inquiries and ensure they receive necessary legal support.
- Market Impact: This investigation may negatively affect agilon health's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Agilon Health securities between February 26, 2025, and August 4, 2025, that they must apply to be lead plaintiff by March 2, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Agilon Health made false and misleading statements during the class period, resulting in investor losses when the true information became public, indicating significant misjudgments in the company's financial outlook.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling such cases.
See More
- Lawsuit Background: Levi & Korsinsky LLP has notified investors that Agilon Health, Inc. (NYSE: AGL) is facing a class action lawsuit for alleged securities fraud, covering the period from February 26, 2025, to August 4, 2025, aimed at recovering losses for affected investors.
- False Statement Allegations: The complaint alleges that the defendants recklessly issued guidance for 2025 without disclosing significant industry headwinds, resulting in materially false and misleading statements regarding the company's business and prospects.
- Investor Rights: Affected investors have until March 2, 2026, to request to be appointed as lead plaintiff to participate in potential recovery, with no out-of-pocket costs or obligations required, thus lowering the barrier for investor participation.
- Law Firm Expertise: With 20 years of experience in securities litigation, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years, showcasing its expertise in complex securities cases.
See More











